RE:RE:RE:RE:Net Present ValueTencents wrote: The Covid 19 potentiel was clearly indicated by dr ask as being in the circumstances of the pandemic
WHO has downgraded Covid 19 as non pandemic
Its unlikely the findings of dr ask will attract any interest now within the Covid 19 space
As Dr. Kolb noted less than 1 year ago in a news release current treatments don't stop the disease. PGX-YBG can reprogram macrophages and prevent fibrosis in mice. This is an urgent unmet need for those who get lung fibrosis due to COVID or not.
“Until now, we have had very limited treatment options for fibrotic lung disease since approved medications can only slow down the progression of the disease. We are very encouraged by the results from this study showing that PGX-YBG has the ability of reprogramming macrophages to prevent fibrogenesis in mice. If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics,” added Dr. Martin Kolb, a respected Pulmonologist and Professor of Medicine at McMaster University.
“Our initial hypothesis was that PGX-YBG particles could be safely delivered into human lungs. These results provide encouraging confirmation of that hypothesis and bolster our confidence for the continued development toward a potential treatment option for IPF,” stated Gilles Gagnon, President and CEO of Ceapro. “This evidence, along with the latest in-vitro and in-vivo data, provides the validation that PGX-YBG holds significant potential as a therapeutic strategy for a broad spectrum of fibrotic end-point lung diseases such as COVID-19 related lung fibrosis and IPF. With these results now in hand, we are evaluating our pre-planned go/no-go decision for advancement of this program into a Phase 1 clinical trial and expect to provide updates in Q3 of this year.”